No Data
Wanbangde Pharmaceutical Holding Group (002082.SZ): Currently, the sales of Ginkgo Biloba Leaf Capsules have increased in OTC channels and third-party terminals.
Gelonghui November 22nd | Wanbangde pharmaceutical holding group (002082.SZ) stated at an investor event that the company's performance fluctuated mainly due to the impact of centralized procurement of products, particularly significant price reductions after the winning bid for the company's core product, Ginkgo Biloba Leaf Capsules, with a decrease of approximately 54%, affecting the company's revenue and profit situation. With the gradual expansion and normalization of centralized procurement policies and the stabilization of medical and pharmaceutical policies, the company has actively adjusted its marketing strategy to mitigate the pressure brought by centralized procurement. Currently, Ginkgo Biloba Leaf Capsules have shown growth in OTC channels and at the third terminal, phenobarbital injection, and new products such as brotizolam injection.
Wanbangde pharmaceutical holding group (002082.SZ): Some active pharmaceutical ingredients have begun overseas sales business.
Gelonghui, November 21: Wanbangde Pharmaceutical Holding Group (002082.SZ) stated on the investor interaction platform that the company has been laying out its overseas market for many years. 1. In the medical instruments business, the company continues to promote the global strategy of "bringing in and going out" for collaborative development between China and Africa. In 2016, it acquired South Africa's Timac Company and Alite Company, beginning deep cooperation with the South African medical industry. The focus is on implantable devices such as spinal fusion devices and orthopedic joints, medical devices, hospital engineering services, and acting as an agent for multiple internationally renowned and domestic brands in the African market, selling PET-CT, MRI and other medical devices, and providing maintenance services. At the same time, in 2019, "China
Wepon Pharmaceutical Unit's Chlorpromazine Hydrochloride Tablets Passes Regulatory Evaluation
Express News | Wanbangde pharmaceutical holding group: Wholly-owned subsidiary pharmaceutical obtains consistency evaluation registration approval.
A-share traditional Chinese medicine stocks surged, with zhejiang wecome pharmaceutical and many other stocks hitting the limit up.
Gelonghui on November 12: Zhejiang Wecome Pharmaceutical, Wanbangde Pharmaceutical Holding Group, Shaanxi Kanghui Pharmaceutical all hit the daily limit up, TeYi Pharmaceutical Group, China Resources Sanjiu Medical & Pharmaceutical, Xiangxue Pharmaceutical followed the upward trend.
Wan Bond: Report for the third quarter of 2024
No Data
No Data